Could a fixed T-Cell dose make stem cell transplants safer?

NCT ID NCT00959140

Ongoing Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving a fixed number of CD3+ T cells (a type of immune cell) during stem cell transplants from sibling donors leads to more predictable outcomes. Researchers want to see if standardizing the dose reduces variation in complications like graft-versus-host disease. The trial involves 20 patients aged 19 and older.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD3+ T cell depletion (device-based cell selection)
What this could lead to: If successful, this could make stem cell transplants more predictable and reduce complications like graft-versus-host disease.
What could go wrong: This is a small, early-phase study with only 20 participants, so results may not apply broadly. The procedure carries risks including infection and graft failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC STEM CELL TRANSPLANTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOPOIETIC STEM CELL TRANSPLANTATION

Contacts and locations

Locations

University of Alabama Hospital

Birmingham, Alabama, 35294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.